Subscriber access provided by Northern Illinois University
Article
Regional intestinal permeability in dogs: biopharmaceutical aspects for development of oral modified-release dosage forms David Dahlgren, Carl Roos, Pernilla Johansson, Anders Lundqvist, Christer Tannergren, Bertil Abrahamsson, Erik Sjögren, and Hans Lennernas Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.6b00515 • Publication Date (Web): 08 Aug 2016 Downloaded from http://pubs.acs.org on August 10, 2016
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 39
Molecular Pharmaceutics Dahlgren, D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Regional intestinal permeability of four model drugs in dog
intestinal
permeability
1 (32)
1
Regional
2
biopharmaceutical aspects for development of
3
oral modified-release dosage forms
4
Dahlgren, David1; Roos, Carl1; Johansson, Pernilla2; Lundqvist, Anders2; Tannergren, Christer2;
5
Abrahamsson, Bertil2; Sjögren, Erik1; Lennernäs, Hans1*
6
1
Department of Pharmacy, Uppsala University, Uppsala, Sweden
7
2
AstraZeneca R&D, Gothenburg, Sweden
8 9
*Address correspondence to:
10
Hans Lennernäs, PhD
11
Professor in Biopharmaceutics
12
Department of Pharmacy
13
Uppsala University
14
Box 580
15
SE-751 23 Uppsala, Sweden
16
Email:
[email protected] 17
Phone: +46 – 18 471 4317
18
Fax: +46 – 18 471 4223
19 20 21
ACS Paragon Plus Environment
in
dogs:
Molecular Pharmaceutics Dahlgren, D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Regional intestinal permeability of four model drugs in dog
Page 2 of 39 2 (32)
22
Abstract
23
The development of oral modified-release (MR) dosage forms requires an active pharmaceutical
24
ingredient (API) with a sufficiently high absorption rate in both the small and large intestine. Dogs are
25
commonly used in preclinical evaluation of regional intestinal absorption and in the development of
26
novel MR dosage forms. This study determined regional intestinal effective permeability (Peff) in
27
dogs with the aim to improve regional Peff prediction in humans.. Four model drugs—atenolol,
28
enalaprilat, metoprolol, and ketoprofen—were intravenously and regionally dosed twice as a solution
29
into the proximal small intestine (P-SI) and large intestine (LI) of three dogs with intestinal stomas.
30
Based on plasma data from two separate study occasions for each dog, regional Peff values were
31
calculated using a validated intestinal deconvolution method. The determined mean Peff values were
32
0.62, 0.14, 1.06, and 3.66 × 10-4 cm/s in the P-SI, and 0.13, 0.02, 1.03, and 2.20 × 10-4 cm/s in the LI,
33
for atenolol, enalaprilat, metoprolol, and ketoprofen, respectively. The determined P-SI Peff values in
34
dog were highly correlated (R2=0.98) to the historically directly determined human jejunal Peff after a
35
single-pass perfusion. The determined dog P-SI Peff values were also successfully implemented in GI-
36
Sim software to predict the risk for overestimation of LI absorption of low permeability drugs. We
37
conclude that the dog intestinal stoma model is a useful preclinical tool for determination of regional
38
intestinal permeability. Still, further studies are recommended to evaluate additional APIs, sources of
39
variability, and formulation types, for more accurate determination of the dog model in the drug
40
development process.
41
………
42
Keywords: dog intestinal permeability, regional intestinal drug absorption, bioavailability, effective
43
permeability, pharmacokinetics, intestinal perfusion, pharmaceutical development.
44 45
Abbreviations: fabs – fraction oral dose absorbed, Papp – apparent permeability, Peff – effective
46
permeability, P-SI – proximal small intestine, LI – Large intestine
ACS Paragon Plus Environment
Page 3 of 39
Molecular Pharmaceutics Dahlgren, D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Regional intestinal permeability of four model drugs in dog
3 (32)
47
Introduction
48
Oral drug treatment is the most common route of administration for pharmaceutical products. Based
49
on units sold and total revenues, the top 50 prescription drugs in the US that are oral products account
50
for 58% of all units sold and 44% of total revenues (IMS Health 2013). The fraction of the oral dose
51
absorbed (fabs) across the apical membrane of the intestine is primarily governed by the drug's
52
solubility, its dissolution rate within the gastrointestinal (GI) lumen, and its effective intestinal
53
permeability (Peff). These biopharmaceutical parameters are the cornerstones of the Biopharmaceutics
54
Classification System (BCS).1 The transport of drugs across the intestinal barrier at various sites
55
occurs by a coexistence of passive and carrier-mediated (CM) trans-epithelial processes.2 The
56
intestinal permeability of BCS class I and II drugs is sufficiently high in both the small and large
57
intestine to not be rate-limiting in drug absorption.3 Still, regional permeability differences for BCS
58
class I and II drugs are important to consider when adjusting the release rates to optimize the
59
pharmacodynamic properties of any modified-release (MR) product. Given that the solubility and
60
dissolution are sufficient, development of a MR dosage form is feasible. This is illustrated by the BCS
61
class I and II drugs metoprolol and nifedipine that have absorption times as MR products up to 20 h
62
post oral dosing.4,5 However, there is a gap in the understanding as to which molecular characteristics
63
that determine regional intestinal absorption rate, regardless of the compound's BCS classification. For
64
instance, it has been reported that the development of MR dosage forms was considered very difficult
65
(59%) or challenging (6%) for novel drugs, due to low absorption in the distal intestinal tract.6 The
66
IMI project (OrBiTo) states that improved understanding of regional intestinal absorption for drugs
67
with different physicochemical properties is a primary research objective.7
68 69
To further improve the accuracy of the development process, there is a need to increase the
70
understanding of the preclinical models used to characterize regional intestinal absorption rate and in
71
vivo formulation performance. The dog absorption model, together with predictive in silico software,
72
are commonly used for this purpose in industrial settings.8 The size of the dog (around 10-40 kg)
73
enables administration of clinical formulations, and dogs have GI anatomy, biochemistry, and
ACS Paragon Plus Environment
Molecular Pharmaceutics Dahlgren, D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Regional intestinal permeability of four model drugs in dog
Page 4 of 39 4 (32)
74
physiology comparable to that of humans, although diet, age and breed can affect the absorption
75
assessment in dogs.9,10 The similarities and differences need to be better understood, especially
76
regional permeability, for accurate trans-species extrapolation of intestinal permeability data from
77
different intestinal sites in the dog. These considerations are fundamental for accurate trans-species
78
extrapolation of intestinal permeability data from different sites in the dog. To date, absorption rate in
79
dog is mainly based on PK data following oral and intraluminal administrations, while direct in vivo
80
determination of intestinal permeability is limited.11-13 Hence, there is a need to improve the
81
understanding of the factors determining regional Peff of drugs in dogs, as well as the experimental
82
design of the dog preclinical absorption model.14 Understanding the dog absorption model and
83
subsequent implementation of dog Peff data into in silico tools is crucial for more accurate use of the
84
model. This is especially important as several of these theoretical in silico models are not fully
85
validated regarding the contribution of the large intestine (LI) to the overall absorption and their
86
potential for MR product development.15,16
87 88
The main objective of this study was to assess the usefulness of dog transabdominal stomas in drug
89
permeability studies. The Peff was measured in the proximal small intestine (P-SI) and LI for four
90
physicochemically diverse model drugs (atenolol, enalaprilat, metoprolol, and ketoprofen). These
91
model drugs are classified as BCS class III, III, I, and II, respectively, and are transported mainly by
92
passive lipoidal and/or paracellular diffusion in all intestinal regions. The regional Peff values were also
93
evaluated regarding their predictive value for simulation of human intestinal absorption by a
94
mechanistic absorption in silico model. The predictability of the dog Peff was evaluated by simple
95
molecular descriptors. Finally, the Peff values were compared to directly determined human jejunal in
96
vivo Peff (single-pass perfusion) and regional in vivo Peff with a novel and validated deconvolution
97
method.17,18
98
ACS Paragon Plus Environment
Page 5 of 39
Molecular Pharmaceutics Dahlgren, D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Regional intestinal permeability of four model drugs in dog
5 (32)
99
Methods
100
Chemicals
101
Atenolol and metoprolol tartrate were provided by AstraZeneca AB (Mölndal, Sweden). Enalaprilat
102
and ketoprofen were purchased from Sigma-Aldrich (St. Louis, MO, US). Sodium phosphate dibasic
103
dihydrate (Na2HPO4·2H2O) and sodium chloride (NaCl) were purchased from Merck KGaA
104
(Darmstadt, Germany). Sterile saline sodium chloride (0.9%) used for injection and dilution was
105
purchased from B. Braun Melsungen (Melsungen, Germany). Water used in the buffer was purified
106
using a Milli-Q water purification system (Millipore Corporation, Billerica, MA). Rifen vet®,
107
(ketoprofen) 100 mg/mL solution for injection was purchased from Salfarm Scandinavia AB
108
(Helsingborg, Sweden). Seloken® (metoprolol tartrate), 1 mg/mL solution for injection was purchased
109
from AstraZeneca AB (Södertälje, Sweden).
110 111
Model drugs
112
Some physicochemical properties of the four model drugs are summarized in Table 1. The doses used
113
in this study were chosen based on the safety considerations in the cassette dosing.
114 115
The four intravenous (iv) solutions of the drugs were prepared separately with a volume of 2 mL and
116
were administered sequentially. The iv solutions for atenolol (0.25 mg/mL, 470 µM) and enalaprilat
117
(0.25 mg/mL, 359 µM) were prepared by dissolving the drugs in saline for injection. The iv solutions
118
of metoprolol (0.19 mg/mL, 468 µM - 0.25 mg/mL as metoprolol tartrate) and ketoprofen (1.25
119
mg/mL, 4.92 mM) were prepared by diluting the commercially available products Seloken®
120
(metoprolol tartrate 1 mg/mL) and Rifen vet® (100 mg/mL), respectively, with saline for injection.
121 122
The isotonic (294 mOsm) drug solution for intraluminal administration in the P-SI and LI was
123
prepared as a cassette dose as follows: atenolol 5 mg (1.88 mM), enalaprilat 20 mg (5.75 mM),
124
metoprolol 12.5 mg (16.25 mg as tartrate salt, 4.68 mM), and ketoprofen 2.5 mg (0.98 mM). All drugs
125
were dissolved in 10 mL isotonic phosphate buffer containing 118 mg Na2HPO4·2H2O (67 mM), 27
ACS Paragon Plus Environment
Molecular Pharmaceutics Dahlgren, D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Regional intestinal permeability of four model drugs in dog
Page 6 of 39 6 (32)
126
mg NaCl (46.2 mM) and 2M HCl to pH 6.8. No incompatibility or degradation of the four study drugs
127
in solution (pH 6.8, 37 °C) was observed during 4 h.
128 129
Animals and study design
130
This preclinical study was approved by the local ethics committee for animal research (no: 34-2015) in
131
Göteborg, Sweden. The study included 3 male Labrador dogs (age: 2-3 years; weight: 37-40 kg)
132
supplied from Jonas Falck, Norway. At 12 months of age, the dogs had two permanent nipple-valve
133
stomas surgically inserted into the abdomen wall, creating direct connections to the P-SI and LI
134
lumen.19 During the first study period, each dog received one iv and two intraluminal administrations
135
(P-SI and LI). The intraluminal administrations were repeated at a second study period, four months
136
later. There was at least one week washout between all drug administrations in each study period. The
137
repeated intraluminal dosing into the same site was performed to better understand intra-dog
138
variability. The dogs were fasted 20 h prior and 4 h post drug dosing. The dogs had access to water ad
139
lib until the administration and from 3 h post dosing. No adverse events were observed during
140
continuous monitoring by the animal staff.
141 142
The four model drugs were administered separately and sequentially on the same day. The
143
administration order and doses were as follows: metoprolol 0.39 mg, atenolol 0.5 mg, ketoprofen 2.5
144
mg, and enalaprilat 0.5 mg. The drugs were administered as bolus doses within 2 min of each other
145
through the same catheter in a peripheral vein in the back leg (vena saphena) to establish individual
146
references. The catheter was rinsed with 2 mL saline after each of the four iv administrations. The
147
administration and rinsing time for each drug was 30 s in total.
148 149
The intraluminal administration and doses were: atenolol 5 mg, enalaprilat 20 mg, metoprolol 12.5
150
mg, and ketoprofen 2.5 mg. These were administered as 10-mL cassette dose solutions with a thin,
151
prefilled plastic tube directly into the P-SI or LI through the transabdominal stoma. The administration
152
time was 2 min.
153
ACS Paragon Plus Environment
Page 7 of 39
Molecular Pharmaceutics Dahlgren, D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Regional intestinal permeability of four model drugs in dog
7 (32)
154
Blood samples of 1 mL were taken from a peripheral vein (routinely rotated) in the front leg, back leg,
155
or neck (vena cephalica, vena saphena or vena jugularis), for a total volume of 12 and 11 mL during
156
the iv and the intestinal administrations, respectively. Blood was sampled immediately before the iv
157
administration and over 24 h (at 5, 10, 20, 30, 40, 50, 60 min, and 2, 4, 6, 8 and 24 h). For the
158
intraluminal administration, blood was sampled immediately before administration and during 6 h
159
after (at 5, 10, 20, 30, 40, 50, 60 min, and 2, 4, and 6 h). The blood samples were put on ice and
160
centrifuged (3000 × g, 10 min at 4 °C) within 20 min. 50 µL of the plasma was transferred to a 1-mL
161
96-well plate (Thermo Scientific) and the remaining plasma was transferred to 2 mL tubes (Sarstedt)
162
for storage. The plasma samples were frozen and stored at -20 °C until analysis.
163 164
Plasma pharmacokinetic (PK) calculations
165
Descriptive plasma PK parameters were calculated following the iv and intraluminal administrations
166
using non-compartmental analysis in WinNonlin software version 6.3 (Certara, L.P.,St. Louis,
167
Missouri). Calculations of the iv PK data were corrected for the difference in injection times for each
168
of the four model drugs. These PK parameters included: area under the plasma concentration-time
169
curve (AUC), maximum plasma concentration (Cmax), apparent volume of distribution at steady state
170
(VSS), and plasma clearance (CL). PK parameters derived from the intraluminal doses included: AUC,
171
Cmax and time to reach maximum concentration (Tmax). The AUC from 0 to 24 h (AUC0-24) and infinity
172
(AUC0-∞) were calculated following the iv administration, and from 0 to 6 h (AUC0-6) following P-SI
173
and LI administration. The AUC0-6, Cmax, and Tmax following the P-SI and LI administrations for each
174
dog used in the statistical analysis (parametric paired t-test, p